MedTrace Logo

Valvular Heart Disease in Women Registry

NCT07196930 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2025-09-29

No results posted yet for this study

Summary

Valvular heart disease (VHD) is a major global health issue. Untreated rheumatic heart disease persists in many regions, preventable with timely care. Higher-income countries face rising calcific valve disease from aging, worsened by VHD complications, like infective endocarditis, resulting in higher morbidity/mortality. Gender disparities in VHD remains understudied, despite inequalities in risks, diagnosis, and treatment. Prevalence varies by gender, but uneven diagnostics and therapies obscure realities. This registry will examine gender disparities from hospital admission to first outpatient follow-up, recruiting both men and women to investigate and report the study objectives.

Conditions

  • Valve Disease, Heart
  • Gender Bias
  • Guideline Adherence
  • Guideline Implementation
  • Disparities
  • Registry

Sponsors & Collaborators

  • European Association of Cardiovascular Imaging

    collaborator OTHER

  • Valvular Heart Disease in Women Registry

    lead NETWORK

Principal Investigators

  • Julia Grapsa, MD PhD · Harvard Medical School (HMS and HSDM)

  • Ana G Almeida, MD PhD · Lisbon University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2027-12-31
Completion
2030-12-31

Countries

  • Egypt
  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07196930 on ClinicalTrials.gov